Biotronik study shows further cost benefits of Home Monitoring

Biotronik has highlighted data from a new study called ECOST which further underlines the cost-effectiveness benefits provided by its Home Monitoring system.

The study has shown how remote monitoring has significantly reduced the cost of follow-up in patients with implantable defibrillators for the French National Health Insurance system, in addition to being safe and efficient.

Over a 27-month follow-up period, ambulatory expenses were significantly reduced, while hospital costs were not significantly different.

In total, it was calculated that the savings generated by Biotronik Home Monitoring came to 315 euros (260.36 million pounds) per patient per year, including the cost of the remote monitoring service.

Christoph Bohmer, international president of Biotronik, added: "The European Society of Cardiology's recent recommendation for using implant-based remote monitoring indicates that remote monitoring will play an even greater role in the future."

This comes after the firm received a recommendation from professor and cardiologist Dr Dietrich Andresen for its BioMonitor monitoring device last month.